Literature DB >> 2186487

Cellular sources of noncollagenous matrix proteins: role of fat-storing cells in fibrogenesis.

A M Gressner1, M G Bachem.   

Abstract

The main types of noncollagenous ECM proteins in liver are FN, laminin, PGs and elastin. Also present is a pure carbohydrate polymer, hyaluronic acid. Their concentrations increase during fibrogenesis in a specific sequence and spatial distribution. FN is among the first to appear. The accumulation of matrix proteins in the space of Disse (perisinusoidal fibrosis) is most important for some clinical consequences of fibrosis. Perisinusoidal FSC are the cell type responsible for exaggerated ECM formation at sites of tissue injury, since these cells synthesize at a high rate in vitro all the noncollagenous matrix components occurring in fibrotic liver matrix (FN, laminin, dermatan sulfate, chondroitin sulfate, hyaluronic acid) and since FSC proliferate and transform into myofibroblast-like cells with an enhanced matrix protein synthesis rate. Recent experimental data suggest strong cellular cooperation of these cells with activated liver macrophages or Kupffer cells, platelets, and regenerating hepatocytes, which leads via a paracrine mechanism involving TGF beta, TGF alpha/EGF, PDGF, and probably other cytokines to stimulated proteoglycan synthesis, proliferation, and transformation into myofibroblast-like cells. The latter cell type has the potential of auto-stimulation (by an autocrine process) involving secretion of TGF beta and TGF alpha/EGF. Based on these findings, a model of FSC activation is proposed (Fig. 10).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2186487     DOI: 10.1055/s-2008-1040455

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  37 in total

1.  Soluble Arg-Gly-Asp peptides reduce collagen accumulation in cultured rat hepatic stellate cells.

Authors:  H Iwamoto; H Sakai; K Kotoh; M Nakamuta; H Nawata
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

2.  Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis.

Authors:  H Herbst; T Wege; S Milani; G Pellegrini; H D Orzechowski; W O Bechstein; P Neuhaus; A M Gressner; D Schuppan
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Liver fibrosis.

Authors:  A D Burt
Journal:  BMJ       Date:  1992-09-05

4.  Myofibroblasts in hepatitis B related cirrhosis and hepatocellular carcinoma.

Authors:  K Y Chau; M A Lily; P C Wu; W L Yau
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

5.  Collagen binding alpha2beta1 and alpha1beta1 integrins play contrasting roles in regulation of Ets-1 expression in human liver myofibroblasts.

Authors:  Iya Znoyko; Maria Trojanowska; Adrian Reuben
Journal:  Mol Cell Biochem       Date:  2006-01       Impact factor: 3.396

6.  Sinusoidal endothelial liver cells in vitro release endothelin--augmentation by transforming growth factor beta and Kupffer cell-conditioned media.

Authors:  H Rieder; G Ramadori; K H Meyer zum Büschenfelde
Journal:  Klin Wochenschr       Date:  1991-06-18

7.  Immunolocalization of proliferating perisinusoidal cells in rat liver.

Authors:  S J Johnson; J E Hines; A D Burt
Journal:  Histochem J       Date:  1992-02

8.  Clinical associations of hepatic stellate cell (HSC) hyperplasia.

Authors:  Taofic Mounajjed; Rondell P Graham; Schuyler O Sanderson; Thomas C Smyrk
Journal:  Virchows Arch       Date:  2014-05-09       Impact factor: 4.064

Review 9.  Is hepatic lipogenesis fundamental for NAFLD/NASH? A focus on the nuclear receptor coactivator PGC-1β.

Authors:  Simon Ducheix; Maria Carmela Vegliante; Gaetano Villani; Nicola Napoli; Carlo Sabbà; Antonio Moschetta
Journal:  Cell Mol Life Sci       Date:  2016-08-13       Impact factor: 9.261

10.  Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo.

Authors:  D C Rockey; C N Housset; S L Friedman
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.